BioInvent International

Declaration of Voting Results & Voting Rights Announcements • Apr 30, 2012

PRESS RELEASE 30 April 2012

New number of shares and votes in BioInvent International AB (publ)

Lund, Sweden – 30 April 2012 - BioInvent International AB (publ) (OMXS:BINV) today announced that the company's total number of shares as per 30 April 2012 amounts to 73,925,782 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the rights issue of 6,720,525 shares with preferential right for the company's shareholders that was announced on 14 February 2012.

--END--

To the editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by n-CoDeR® , a proprietary antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB

Svein Mathisen Sten Westerberg President & CEO Vice President, Investor Relations Mobile: +46 (0)708 97 82 13 Mobile: +46 (0)768 68 50 09 E-mail: svein.mathisen@bioinvent.com E-mail: sten.westerberg@bioinvent.com

College Hill (media enquiries) Melanie Toyne Sewell, Anastasios Koutsos Tel: +44 (0)20 7866 7856 Rebecca Skye Dietrich Phone: +1 (857) 241 0795 E-mail: bioinvent@collegehill.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263, Visiting address: Sölvegatan 41 Mailing address: SE-223 70 LUND

Phone: +46 (0)46 286 85 50 info@bioinvent.com www.bioinvent.com

Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 30 April 2012.